Dise RS, Frey MR, Whitehead RH, Polk DB. Epidermal growth factor stimulates Rac activation through SRC and phosphatidylinositol 3-kinase to promote colonic epithelial cell migration.
THE INTESTINAL EPITHELIUM forms a dynamic barrier between the contents of the gastrointestinal tract and the organism. Maintenance of this barrier, comprised of a single layer of epithelial cells that is renewed every 2-5 days in humans, is critical for normal growth, development, and disease prevention. The intestinal epithelium is continually exposed to noxious substances present in the lumen of the gut, which can damage the monolayer and compromise its barrier function. Immediately following injury, epithelial cells surrounding the wound lose their columnar polarity, taking on a flattened morphology, and rapidly migrate into the denuded area to restore barrier integrity (3, 19) . This rapid restitution is critical for maintenance of a healthy gastrointestinal tract, and impaired wound healing is thought to contribute to chronic gastrointestinal disorders such as inflammatory bowel disease (IBD) (5) .
A number of soluble growth factors present in the lumen, including the epidermal growth factor receptor (EGFR) ligands, transforming growth factor-␣ (TGF-␣), and EGF (36, 50) , trefoil factor peptides (15) , and TGF-␤ (16), accelerate restitution in in vitro and in vivo models of intestinal injury, suggesting these factors may be beneficial for patients with pathologies involving intestinal ulceration such as IBD. In particular, absence of EGFR ligands is associated with spontaneous or increased susceptibility to experimental IBD in several mouse models (17, 27, 47) . Furthermore, administration of EGF-containing enemas has been reported to induce remission in patients with ulcerative colitis (44) , demonstrating that EGFR-mediated wound healing is a promising therapeutic approach for IBD in humans. These findings emphasize the importance of studies to increase our understanding of the molecular mechanisms by which EGFR ligands enhance intestinal epithelial restitution and repair.
Following ligand binding, EGFR dimerizes, acquires increased tyrosine kinase activity, and becomes highly phosphorylated on C-terminal cytoplasmic tyrosine residues that provide a platform for recruitment and activation of downstream signaling modules including mitogen-activated protein kinase (MAPK) cascades (25, 39) , phosphatidylinositol 3-kinase (PI3K) (37) , phospholipase C (PLC)-␥ (2), and Src family kinases (32) . Using an in vitro model of wound healing, we have previously shown that EGF stimulates migration of young adult mouse colonic epithelial (YAMC) cells surrounding a wound in the monolayer (14, 21) . Although EGFR-stimulated cell proliferation has been exhaustively characterized (reviewed in Refs. 13 and 41) the signaling pathways that promote restitution downstream of EGFR are not as well defined. The process of cell migration requires tight regulation of the actin cytoskeletal organization, which is controlled by members of the Rho family of small GTPases Cdc42, Rac, and Rho (reviewed in Ref. 34) . Rho GTPases cycle between an active GTP-bound state and an inactive GDP-bound state, regulated by guanine nucleotide exchange factors (GEFs), which catalyze the exchange of GTP for GDP and GTPase activating proteins (GAPs), which stimulate the intrinsic GTPase activities of Rac, Rho, or Cdc42. When Rho GTPases are activated, a C-terminal prenylation site promotes translocation to the plasma membrane (reviewed in Refs. 38 and 43) initiating signaling pathways involved in modification of the actin cytoskeleton through downstream effector proteins that specifically recognize and bind to the GTP-bound form of the GTPase.
Data from several model systems implicate Rho GTPases as critical regulators of wound healing (reviewed in Ref. 48 ). In fibroblast migration assays, formation of lamellipodia at the leading edge of cells requires Rac activation (29) . In this regard, extension of lamellipodia is the first visible sign of restitution following intestinal epithelial erosion both in vivo and in vitro (19, 20) . Additionally, expression of dominant negative Rac1 in the mouse small intestine slowed enterocyte cell migration along the crypt-villus axis, implicating this small GTPase in the normal turnover and maintenance of the intestinal epithelium (45) . As rapid cell migration is critical for proper restitution in the gastrointestinal tract, we hypothesized that the small GTPase Rac is also required for EGF-stimulated intestinal epithelial wound closure. Here we demonstrate that Rac, but not the related Rho GTPase Cdc42, is required for EGF-stimulated wound closure via a signal transduction pathway dependent upon both PI3K and Src family kinases. These data link EGFR activation in intestinal epithelial cells to increased motility and wound closure requiring Rac activation.
MATERIALS AND METHODS
Cell culture. The conditionally immortalized YAMC cell line isolated from the colonic epithelium of H-2K b -tsA58 (Immorto) mice has been previously described (49) . EGFR-null mouse colonic epithelial (MCE) (EGFR Ϫ/Ϫ MCE) cells were isolated in the Vanderbilt Digestive Disease Research Center Novel Cell Line Core from the colonic epithelium of EGFR-null heterozygous mice crossed with the Immorto mouse (46, 49) . Cells were maintained on rat tail collagen-(Mediatech, Herndon, VA) coated plates (5 g/cm 2 ) in RPMI 1640 supplemented with 5% FBS, 5 U/ml mouse IFN-␥ (Intergen, Norcross, GA), 100 U/ml penicillin and streptomycin, 5 g/ml insulin, 5 g/ml transferrin, and 5 ng/ml selenous acid (BD Biosciences, San Jose, CA) at 33°C (permissive conditions). Before all experiments, cells were serum starved for 16 -18 h in RPMI 1640 containing 0.5% FBS and 100 U/ml penicillin and streptomycin with no interferon at 37°C (nonpermissive conditions).
Antibodies, growth factors, and inhibitors. FITC-conjugated goat anti-mouse secondary antibody was from Jackson ImmunoResearch Labs (West Grove, PA). Mouse monoclonal Rac and rabbit polyclonal EGFR antibodies were from Upstate (Charlottesville, VA). Mouse monoclonal EGFR antibody conjugated to phycoerythrin, EGFR (528) PE, (Santa Cruz Biotechnology, Santa Cruz, CA) was used for fluorescence-activated cell-sorting (FACS) analysis. Mouse monoclonal hemagglutinin (HA)-Tag (262K), rabbit monoclonal pY1173 EGFR, rabbit polyclonal phospho-Akt (Ser 473) and pY925 FAK antibodies, and horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody were from Cell Signaling Technology (Beverly, MA). Anti-active ERK1 and 2 polyclonal antibody was from Promega (Madison, WI). Mouse monoclonal actin antibody was from SigmaAldrich (St. Louis, MO). Mouse monoclonal Cdc42 antibody and HRP-conjugated goat anti-mouse IgG was from BD Transduction Laboratories (San Diego, CA). Murine EGF was a gift from Stanley Cohen (Vanderbilt University, Nashville, TN). Rac1 inhibitor NSC23766, U0126, wortmannin, and LY294002 were from Calbiochem (San Diego, CA). PP1 and PP2 were from Biomol (Plymouth Meeting, PA). Src inhibitor CGP77675 was a gift from Anna Suter (Novartis, Basel, Switzerland).
Generation Migration assays. Cells were seeded onto 35-mm plates coated with 2.5 g of human fibronectin (BD Bioscience, Bedford, MA). Six circular wounds were made in each confluent plate by using a rotating silicon tip as previously described (14) . The cells were washed twice with PBS and incubated at nonpermissive conditions with or without 10 ng/ml EGF. For migration assays with the use of inhibitors, cells were pretreated with inhibitor for 45 min before wounding, and then fresh inhibitor was added after wounding. Wounds were photographed at 0 and 8 h after wounding, and the size of each wound was determined using ImageJ software (National Institutes of Health, Bethesda, MD). The percent wound closure after 8 h was calculated. Values shown are the average wound closure rates for all six wounds Ϯ SD.
Immunofluorescence. YAMC cells cultured on fibronectin-coated glass chamber slides were wounded as described above, then washed twice with PBS, and incubated with or without 10 ng/ml EGF for 10 min. Cells were fixed in 4% paraformaldehyde-PBS and permeabilized with 0.4% Triton X-100 in PBS. The cells were then stained with a monoclonal Rac antibody (1:50) followed by anti-mouse FITC secondary. Coverslips were mounted by using the Prolong Antifade Kit (Molecular Probes) and imaged on a Zeiss Axiovert 200 microscope.
Cell lysates, SDS-PAGE, and Western blot analysis. Cells were washed twice with cold PBS and lysed in Rac lysis buffer [50 mM Tris ⅐ HCl (pH 7.5), 10 mM MgCl 2, 200 mM NaCl, 1% (vol/vol) Nonidet P-40, 5% (vol/vol) glycerol] with protease and phosphatase inhibitor cocktails (Sigma). Lysates were cleared by centrifugation, protein concentrations were determined with the DC protein assay (Bio-Rad Laboratories, Hercules, CA), and 25 g of each sample were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked in 5% (wt/vol) nonfat dry milk in Tris-buffered saline (50 mM Tris, 138 mM NaCl, 2.7 mM KCl, pH 8.0) with 0.05% Tween 20 (TBST) for 1 h. Membranes were probed with primary antibody at 4°C overnight, washed in TBST (6 ϫ 5 min), incubated with HRP-conjugated secondary antibody for 1 h, and then washed in TBST (6 ϫ 5 min). Bound HRP was detected by using Western Lightning enhanced chemiluminescence kit (Perkin-Elmer, Boston, MA).
Rac activation assays. Rac activation was assayed as previously described (7). Briefly, the p21-binding domain (PBD) of PAK fused to glutathione S-transferase (GST) was expressed from pGEX-PBD, a gift from Josephine Adams (University College of London, London). Recombinant GST-PBD was purified with glutathione-Sepharose 4B beads (Pharmacia, Piscataway, NJ). Immediately after treatment, cells were lysed in Rac lysis buffer, and 1 mg of total lysate was nutated with GST-PBD beads at 4°C for 1 h. Beads were collected by centrifugation and were washed three times with washing buffer [25 mM Tris ⅐ HCl (pH 7.6), 1 mM DTT, 30 mM MgCl2, 40 mM NaCl, 1% (vol/vol) Nonidet P-40] and twice with washing buffer without Nonidet P-40. Proteins were eluted by boiling beads in 2ϫ Laemmli sample buffer for 5 min, separated on a 15% SDS-polyacrylamide gel, and blotted for Rac.
Statistical analysis. Statistical significance between control and test conditions was determined using a paired two-sample Student's t-test with a confidence level of 0.05. All data presented are representative of at least three independent experiments.
RESULTS

EGF stimulates Rac membrane translocation and increased lamellipodia formation.
We have previously reported that YAMC cells treated with EGF show increased rates of wound closure in an assay that mimics ulceration in vivo (14, 21) . As lamellipodia formation is typically the first visible sign of restitution of experimental wounds (19), we hypothesized that EGF stimulates cell migration through increased lamellipodia formation. To test this idea, circular wounds were made in confluent monolayers of YAMC cells, and cultures were incubated with or without EGF for 10 min. The percentage of cells exhibiting visible lamellipodia at the wound margin was visualized by phase contrast microscopy and quantified. As shown in Fig. 1A , EGF stimulates a twofold increase in the percentage of cells with lamellipodia at the wound margin (35.97 Ϯ 7.53 vs. 17.98 Ϯ 4.48%).
It has been well documented in fibroblasts that activation and accompanying plasma membrane translocation of the small GTPase Rac is required for lamellipodia formation (35) . Therefore, we next immunolocalized Rac in wounded YAMC cells in the absence or presence of EGF to determine whether EGFR signaling stimulates Rac membrane translocation during the first minutes of restitution. YAMC cells treated with EGF for 10 min exhibited prominent Rac staining at the wound margins that was not detected in control cells (Fig. 1, B and C) . These data confirm that EGF enhances lamellipodia formation and Rac membrane localization at the wound margin.
Rac activation and expression are required for EGF-stimulated intestinal cell migration. To test the hypothesis that Rac activation is required for EGF-stimulated cell migration, we treated YAMC cells with EGF and measured wound closure after 8 h in the presence or absence of a Rac1 pharmacological inhibitor, NSC23766, which has been shown to specifically inhibit Rac activation without interfering with Cdc42 or Rho (22) . The Rac1 inhibitor completely blocked EGF-stimulated wound closure compared with cells treated with vehicle alone (Fig. 2A) . To determine the specificity of Rac regulation of EGF-stimulated migration, YAMC cells were transfected with nontargeting, Rac1, or Cdc42 siRNA pools and subjected to migration assays. Western blot analysis of the cells used in the migration assay confirmed that Rac1 and Cdc42 protein levels were decreased by siRNA transfection (data not shown). EGFstimulated wound closure was completely blocked in cells transfected with Rac1 siRNA but not in cells transfected with either nontargeting or Cdc42 siRNA (Fig. 2B) . Interestingly, both Rac1 inhibitor and Rac1 siRNA decreased basal cell migration, demonstrating that Rac regulates both basal as well as EGF-stimulated migration. In cells transfected with Cdc42 siRNA, basal cell migration was inhibited, but EGF-stimulated migration was not, suggesting that EGF signaling can bypass a requirement for Cdc42.
To define the effect of EGF on Rac activation, we used a GST pulldown assay, which specifically recognizes active, GTP-bound Rac (7) . To determine the specificity of this assay and assess any reciprocal relationship between these Rho GTPase family members, Rac activation was assessed in YAMC cells transfected with nontargeting, Rac1, or Cdc42 siRNAs after a 3-min exposure to EGF (Fig. 2C) . A significant increase in Rac-GTP levels was detected in cells transfected with either nontargeting or Cdc42 siRNA in response to EGF. In cells transfected with Rac1 siRNA, Rac activation was attenuated, consistent with the reduction in Rac1 protein levels, confirming the specificity of the assay. Western blot analysis for Rac and Cdc42 confirmed selective reduction of the siRNA-targeted proteins (Fig. 2C) . Actin Western blot analysis confirmed equal protein loading (Fig. 2C) . These data demonstrate that Rac is activated in response to EGF in a Cdc42-independent manner, consistent with the wound closure assay data in Fig. 2B .
EGFR kinase activity is required for EGF-stimulated Rac activation and migration. To determine the kinetics of Rac activation, YAMC cells were treated with EGF for 0 to 10 min, and GTP-bound Rac levels were assessed. As shown in Fig. 3A , EGF stimulated a robust and rapid activation of Rac within 30 s that was sustained up to 6 min. EGF also promoted Akt and ERK1 and 2 phosphorylation in these cells. Interestingly, detectable activation of these proteins was first observed only after Rac activation, suggesting that the signaling pathways that activate Rac are upstream or independent of cell proliferation (ERK1 and 2) and cell survival (Akt) pathways.
EGF preferentially binds to EGFR among the ErbB receptors (24) , but all four ErbBs are expressed in MCE cells (data not shown). Therefore, we wanted to confirm that EGFR was required for EGF-stimulated Rac activation. EGFR Ϫ/Ϫ MCE cells, which express ErbB2, ErbB3, and ErbB4 but not EGFR, were exposed to EGF for 0 to 60 min (Fig. 3B) . EGF activated Rac in YAMC cells at 3 min but not in the EGFR Ϫ/Ϫ MCE cells at any of the time points tested. Because we observed measurable EGFR and ErbB2 tyrosine phosphorylation in response to EGF in cells expressing kinase dead (K721R) EGFR (Fig. 4A) , suggesting that some EGF-induced signaling can occur in the absence of EGFR kinase activity, it was also important to confirm whether Rac activation is expressly dependent on EGFR kinase activity. Stable expression of wildtype human EGFR, but not kinase dead EGFR or vector, in EGFR Ϫ/Ϫ cells restored EGF-stimulated Rac activation (Fig.  4B) , confirming that receptor kinase activity is required for Rac activation. Expression of wild-type EGFR also restored EGFstimulated Akt and ERK1 and 2 activation, whereas kinase dead EGFR did not. Similarly, in our wound-healing assays, EGFR Ϫ/Ϫ MCE cells stably transfected with wild-type EGFR responded to EGF with an increased wound closure rate similar to YAMC cells (Fig. 4C) (Fig. 5A) ; inhibition of PLC␥1, PKCs, and p38 MAPK also had no effect on EGF-stimulated Rac activation (data not shown). To confirm the efficacy of the PI3K inhibitors, the total cell lysate was blotted for phospho-Akt and phospho-ERK1 and 2, downstream targets of PI3K and MEK1 and 2, respectively. Both of the PI3K inhibitors blocked Akt activation, whereas the MEK1 Fig. 3 . EGF rapidly stimulates Rac activation in YAMC but not EGFR Ϫ/Ϫ mouse colonic epithelial (MCE) cells. A: YAMC cells were treated with EGF for the indicated times, and Rac activation was assessed as in Fig. 2 . The total lysate was blotted for Rac to confirm equal protein levels before the GST-PBD pulldown assay. Activation of Akt and ERK1 and 2 in the total lysate were detected using phospho-specific antibodies. B: YAMC and EGF receptor (EGFR) Ϫ/Ϫ MCE cells were exposed to EGF for the indicated times, and Rac activation was assessed as in A. Fig. 2 . Rac activation and expression are required for EGF-stimulated cellular migration. A: YAMC cells were pretreated for 1 h with 50 M Rac inhibitor NSC23766, then wounded, and exposed to EGF in the presence or absence of the Rac inhibitor. Wounds were photographed after 0 and 8 h, and percent wound closure was calculated. B: YAMC cells were transfected with either 50 nM nontargeting, 50 nM Rac1, or 50 nM Cdc42 small interfering (si)RNA and then wounded and measured as above. C: YAMC cells were transfected with indicated siRNA constructs, and Rac activation was assessed by using glutathione S-transferase (GST)-p21-binding domain (PBD) beads to isolate GTPbound Rac with or without 3 min EGF exposure. Total lysates were prepared for Western blot analysis for Rac, Cdc42, or actin as a loading control. *P Ͻ 0.001 compared with matched untreated cells. @P Ͻ 0.01 compared with vehicle control (A) or nontargeting control (B) cells. and 2 inhibitor blocked activation of ERK1 and 2, as expected (Fig. 5A) . Because Akt is a major downstream target of PI3K, but in our assays is activated by EGF only after Rac (Fig. 3A) , we next wanted to determine if Akt activation is involved in Rac activation. YAMC cells were transfected with dominant negative Akt1 or Akt2 and then subjected to Rac activation assays and Western blot analysis for phospho-Akt. Interestingly, dominant negative Akt slightly decreased overall Rac GTP loading, independent of stimulation (Fig. 5B) . However, consistent with our time course data, expression of dominant negative Akt1 or Akt2 did not abrogate the ability of EGF to stimulate Rac activity (Fig. 5, B and C) . These data demonstrate that PI3K activity is required for EGF-stimulated Rac activation, independent of Akt or MAP kinase activity.
Because Src family kinases are known to play a key role in activation of EGFR and its downstream signaling pathways, we wanted to determine if Src kinases were involved in EGF-stimulated Rac activation. Three different Src family kinase inhibitors, CGP77675, PP1, and PP2, all reduced EGFstimulated Rac activation (Fig. 6A) . At the concentrations used, these inhibitors did not decrease EGF-stimulated EGFR phosphorylation at tyrosine 1173, a major phosphorylation site, or activation of the downstream signaling module ERK1 and 2, but phosphorylation of the Src kinase substrate focal adhesion kinase (FAK) at tyrosine 925 (40) was blocked (Fig. 6A) , confirming that these inhibitors are specific for Src family kinases at the concentrations used in these experiments. To test the requirement for Src family kinases in EGF-stimulated wound closure, YAMC cells were treated with Src inhibitors with or without EGF, and wound closure rates were determined. Consistent with our previous observations (14, 21) , all Src inhibitors blocked EGF-stimulated wound closure (Fig. 6B) . CGP77675, which blocked Rac GTP activation and FAK phosphorylation at tyrosine 925 most effectively, also inhibited EGF-stimulated migration to the greatest extent.
Both Src and PI3K activities are required for maximal Rac activation in response to EGF. Although PI3K and Src inhibitors significantly reduced EGF-induced Rac activation in our studies (Figs. 5 and 6) , neither inhibitor at a range of concentrations produced complete inhibition (data not shown). To test the possibility that Src and PI3K act cooperatively to activate Rac, YAMC cells were treated with DMSO, LY294002, CGP77675, or both LY294002 and CGP77675, and EGFstimulated Rac activation was assessed. The combination of both LY294002 and CGP77675 completely blocked Rac activation in response to EGF but had no effect on EGF-stimulated EGFR activation (Fig. 7A) . Furthermore, EGF-stimulated Rac localization at the leading edge of cells around the wound margin as determined by immunofluorescence analysis was significantly attenuated by the LY294002 and CGP77675 combination (Fig. 7B) . These data confirm that both Src and PI3K contribute to Rac activation in response to EGF, suggesting that these kinases act in concert downstream of EGFR through parallel mechanisms. 
YAMC cells and EGFR
Ϫ/Ϫ MCE cells stably expressing vector, wild-type, or kinase dead EGFR were treated with EGF for 3 min. A: EGFR and ErbB2 were immunoprecipitated and immunocomplexes were subjected to SDS-PAGE and Western Blot analysis using anti-phosphotyrosine antibody. B: Rac activation was assessed as in Fig. 2 . The total lysate was blotted for Rac to confirm equal protein levels before the GST-PBD pulldown assay and for EGFR to compare EGFR expression levels in the stable cell lines. Akt and ERK1 and 2 activation in the total lysate were determined as in Fig. 3 .
C: YAMC cells and EGFR
Ϫ/Ϫ MCE cells stably expressing vector alone, wild-type EGFR, or kinase dead EGFR were wounded with a rotating silicon tip and incubated with or without EGF for 8 h. Percent wound closure was determined by time lapse microscopy as above. *P Ͻ 0.001 compared with matched control. pY, phosphotyrosine.
DISCUSSION
In this study, we have extended our investigation of EGFstimulated wound closure by demonstrating that EGF increases lamellipodial extensions at the wound margin and rapidly activates the small GTPase Rac to enhance colonic epithelial cell migration. We also show that two EGFR signaling targets, Src family kinases and PI3K, cooperate to promote maximal Rac activation in response to EGF. Our data suggest a novel signaling integration downstream of EGFR leading to increased cell motility independent of the proliferative (ERK1 and 2) and cell survival (Akt) pathways that are also stimulated by EGFR. Combined with our previous studies (14, 21) , these results are consistent with a model of intestinal repair in which cellular migration, independent of proliferation, occurs imme- Fig. 2 . Phospho-Y1173 EGFR, phospho-Akt, and phospho-ERK1 and 2 were determined by Western blot analysis of total lysates. B: YAMC cells were transfected with vector, dominant negative Akt1 (DN Akt1), or dominant negative Akt2 (DN Akt2) and then exposed to EGF for 3 min, and Rac activation was assessed as in A. Hemogglutinin (HA)-Akt and phospho-Akt levels were detected by Western blot analysis. C: quantification of Rac activation levels in inhibitor and DN Akt experiments. Values represent the average of at least 3 independent experiments. *P Ͻ 0.001 vs. control. Fig. 6 . Src family kinases are required for EGF-stimulated Rac activation and cell migration. Serum-starved YAMC cells were incubated with 2 M CGP77675, 12.5 M PP1, or 7.5 M PP2 for 1 h. A: cells were treated with EGF for 3 min. Rac activation was assessed as above. Total lysates were blotted for Rac to confirm equal protein levels before the GST-PBD pulldown assay. Activation of focal adhesion kinase (FAK), EGFR, and ERK1 and 2 were detected by using the indicated phospho-specific antibodies. B: wounds were prepared as above, and percent wound closure was determined with or without EGF. *P Ͻ 0.001 compared with matched untreated cells. @P Ͻ 0.01 compared with vehicle untreated cells.
diately after wounding to restore epithelial integrity, followed by a proliferative phase to repopulate the damaged area (31) .
In response to injury, epithelial cells at the wound margin sense the loss of neighboring cells, extend lamellipodia, and begin to migrate into the denuded area to close the wound (26) . Although EGF stimulates increased migration in YAMC cells in our wound closure assay, lamellipodial extension and cell movement into the denuded area do still occur in the absence of exogenous growth factor, albeit with reduced kinetics (Fig.  1, A and B; Fig. 2, A and B, untreated cells) . Scrape wounding alone weakly activates Rac in YAMC cells, presumably only in the cells adjacent to the wound margin (R. Dise and D. Polk, unpublished observations), yet this activation appears to be important for restitution because both Rac inhibitor and Rac siRNA significantly decrease basal migration (Fig. 2) , as do Src or PI3K inhibitors (Fig. 6) (18) . Thus Src, PI3K, and Rac are effectors of both growth factor stimulated and basal migration, unlike some EGF-stimulated pathways such as p38 MAPK, which, at least in the YAMC cell model, is required for growth factor-induced but not basal wound healing (21) . We hypothesize that one mechanism whereby EGF promotes colonic epithelial restitution is via more rapid and robust Rac activation in cells surrounding the wound margin because they both sense the denuded area and take up ligand, reinforcing signaling downstream of EGFR to enhance cellular migration. Thus EGFR stimulates both signals shared with basal restitution mechanisms and those unique to growth factor-accelerated wound healing (e.g., p38 MAPK). However, it is still unclear whether the signals intermediate of EGFR and Rac are similar to those by which mechanical wounding activates Rac and whether EGFR plays any role in the latter response, especially given that intestinal epithelial cells lacking EGFR do undergo restitution, despite an inability to respond to EGF (21) . Interestingly, studies have demonstrated that filopodial extensions direct the formation of lamellipodia, suggesting that Cdc42 is upstream of Rac activation (30) in unstimulated migration. Consistent with this idea, we observed that transfection of cells with Cdc42 siRNA significantly inhibits basal cell migration in untreated cells (Fig. 2B) . However, Cdc42 siRNA did not attenuate migration in cells exposed to EGF, implying that this small GTPase, unlike Rac, is dispensable for growth factorinduced restitution. Similarly, we were unable to detect Cdc42 activation in response to EGF (data not shown), and Cdc42 siRNA did not inhibit EGF-stimulated Rac activation (Fig.  2C) , again uncoupling growth factor-induced Rac activation and migration from Cdc42.
Akt phosphorylation in response to growth factor-stimulated PI3K activation has been well defined (reviewed in Ref. 11) , and PI3K and Akt activity are often thought to be equivalent. EGFR ligands activate PI3K, increasing cellular membrane PI-3,4,5-P 3 , which initiates membrane localization of proteins containing plekstrin homology (PH) domains, such as Akt. In our studies, pharmacological inhibition of PI3K with LY294002 and wortmannin in YAMC cells decreases both Akt and Rac activation in response to EGF (Figs. 5 and 7) . However, EGF-stimulated Rac activation in YAMC cells is maximal before maximal Akt activation (Fig. 3A) , and a dominant-negative Akt fails to attenuate Rac activation (Fig.  5B) . Thus PI3K appears to mediate Rac activation via a yet to be identified alternative substrate. . Src and PI3K both contribute to maximal Rac activation in response to EGF. YAMC cells were incubated with inhibitors as above or with both 50 M LY294002 and 2 M CGP77675 for 1 h. A: cells were exposed to EGF for 3 min. Rac activation was analyzed using GST-PBD beads to isolate GTP-bound Rac. Activation of EGFR, FAK, and Akt were detected in the total lysate by using phospho-specific antibodies as indicated. B: cell monolayers were wounded with or without EGF for 10 min, fixed, and subjected to immunofluorescence localization analysis for Rac as in Fig. 1 . The percentage of cells at the wound margin with Rac at the leading edge was counted. C: percentage of cells at the wound margin with lamellipodial extensions was quantified. *P Ͻ 0.01 vs. control.
EGFR activates another small GTPase, Ras, resulting in increased proliferation through activation of the ERK MAPK cascade (12) . In agreement with our previous findings showing that ERK MAPK signaling is not required for colonic epithelial migration (21) , pharmacological inhibition of the MAPK cascade using a MEK1 and 2 inhibitor, U0126, did not alter Rac activation in response to EGF (Fig. 5A) . These data indicate that the signaling pathways upstream of Rac activation in cultured MCE cells are part of a proliferation-independent phase of wound restitution, mimicking the in vivo response to injury.
Using three different pharmacological Src inhibitors, we demonstrate a requirement for Src family kinase activity in Rac activation. Previous work from our laboratory has shown that Src, Yes, and Fyn are expressed in YAMC cells and become activated in response to EGF (21) . Because Src inhibitors regulate different family members to varying degrees, we attempted to provide further specificity to our analysis by using siRNA pools. However, we were not able to completely knock down individual family members, though some inhibition of Rac activation was observed with both Src and Fyn siRNA (data not shown). One possible function for Src family members in this context is stimulation of a Rac-specific GEF in intestinal epithelial cells. Data suggest that the most important factor influencing GTPase activation is the regulation of GEFs (42) . Presently 85 mammalian GEFs have been identified, most of which contain the characteristic PH domain. Although a small number of GEFs have been well characterized, most are either novel or little is known about their GTPase specificity, making identification of the specific GEF involved in a particular cellular process problematic. Furthermore, although GEF activation is thought to be tightly regulated, a common mechanism of regulation has not been established. Vav2, a GEF for Rho, Rac, and Cdc42, has been shown to coimmunoprecipitate with activated EGFR and is tyrosine phosphorylated in response to EGF treatment of HeLa cells (33) . Although Vav2 is expressed in YAMC cells, we were unable to detect either tyrosine phosphorylation of Vav2 or association of Vav2 with EGFR in response to EGF in YAMC cells (data not shown). An attractive hypothesis consistent with our present data is that the GEF responsible for Rac activation in MCE cells may be activated by Src family kinase tyrosine phosphorylation to relieve an intramolecular inhibition and expose the Dbl homology domain to facilitate exchange, similar to regulation of the hematopoietic-specific GEF Vav1 (1) . Future experiments are required in order to focus on identifying the Src family member involved in Rac activation and identification of potential tyrosine phosphorylated GEFs in these cells that may be Src substrates. Alternatively, it is also possible that regulation of guanine nucleotide dissociation inhibitors (GDIs) or GAPs for Rac may be regulated by Src kinases, or that the role of Src in Rac activation is through Src-specific phosphorylation on EGFR since EGF stimulates phosphorylation of EGFR on tyrosines 845 and 1101 as Src kinase substrates (9) . It is possible that these tyrosine residues activate signaling pathways involved in Rac activation, resulting in the requirement for Src family kinases to phosphorylate EGFR but not the EGF or other targets directly to activate Rac.
Rac activation has long been described as a key mediator of lamellipodial extension and cell migration. In recent years, significant progress has been made with regard to the exact mechanisms by which Rac participates in these processes. For example, direct binding to multifunctional scaffold molecules such as IQ motif and GAP-related domain containing protein 1 (IQGAP1) has been demonstrated to link Rac with rearrangements of the actin cytoskeleton, which promotes lamellipodial protrusion (6) . IQGAP1 appears to serve as both regulator and effector of Rac1 and Cdc42; for example, it can suppress the intrinsic GTPase activity of Cdc42 (23), effectively promoting or sustaining Cdc42-driven signaling. In turn, IQGAP1 can function downstream of Rho family GTPases, driving cytoskeletal rearrangement through interaction with the Arp2 and 3 complex and neural Wiskott-Aldrich syndrome protein (N-WASP) (8, 28) . Although it is not currently known whether EGF signaling through Rac is regulated by PI3K and/or Src at the level of an IQGAP-associated complex, the possibility is intriguing, given recent results implicating direct binding of IQGAP1 to Rac in response to VEGF in neural progenitor (4) and endothelial cells (51) . Interestingly, in the study from Yamaoka-Tojo and colleagues (51) , IQGAP1 served as a scaffold for a complex including Rac1 and the VEGF type 2 receptor; this complex appeared to be required for Akt phosphorylation, cell migration, and cell growth in response to reactive oxygen species. Whether this is a common mechanism shared by other growth factor receptors such as EGFR remains to be determined. IQGAP1 has been identified as an EGFR-binding protein in a proteomic screen (10) , but the physiological significance of this interaction is as yet untested.
Our data indicate a requirement for both Src family kinases and PI3K signaling for maximal Rac activation and extension of lamellipodia in response to EGF. Since GEF activation requires translocation to the plasma membrane through PH domains, an attractive hypothesis in this regard is that PI3K recruits the GEF to the plasma membrane, bringing it into proximity with activated EGFR and Src, where it can be further activated through phosphorylation. The synergistic effect of inhibiting both Src and PI3K suggests that these pathways contribute independently to activation of Rac (Fig. 7) . Because inhibition of PI3K does not block Src activity (Fig. 7) , it is unlikely that PI3K is upstream of Src, and similarly inhibition of Src family kinases does not block Akt phosphorylation, demonstrating that PI3K activation is independent of Src tyrosine kinase activity. Thus our data suggest a model in which PI3K and Src work in parallel to fully activate Rac. Additionally, we find that pharmacological inhibition of PLCs, protein kinase Cs (PKCs), and p38 MAPK does not affect EGFstimulated Rac activation (data not shown). Together, these data demonstrate a novel pathway whereby EGFR signaling increases wound closure through the coordinated activation of two different kinase cascades that induce colonic epithelial cell motility via Rac. These data contribute to our understanding of the complex molecular mechanisms regulating this small GTPase family member, which is critical to the maintenance of an intact intestinal monolayer in vitro and in vivo with implications for colonic epithelial diseases such as ulcerative colitis.
